U.S. Code · Título 21
Actions for delays of generic drugs and biosimilar biological products
21 U.S.C. § 355–2
Office of the Law Revision Counsel · release 119-142
Se muestra el texto operativo de la sección. Las notas estatutarias y el historial de enmiendas están en la fuente oficial.
Definitions
In this section—
the term “commercially reasonable, market-based terms” means—
the term “covered product”—
means—
does not include any drug or biological product that appears on the drug shortage list in effect under section 356e of this title, unless—
the term “sufficient quantities” means an amount of a covered product that the eligible product developer determines allows it to—
conduct testing to support an application under—
Civil action for failure to provide sufficient quantities of a covered product
In general
An eligible product developer may bring a civil action against the license holder for a covered product seeking relief under this subsection in an appropriate district court of the United States alleging that the license holder has declined to provide sufficient quantities of the covered product to the eligible product developer on commercially reasonable, market-based terms.
Elements
In general
To prevail in a civil action brought under paragraph (1), an eligible product developer shall prove, by a preponderance of the evidence—
that—
if the covered product is subject to a REMS with ETASU—
that the eligible product developer has submitted a written request to purchase sufficient quantities of the covered product to the license holder, and such request—
that the license holder has not delivered to the eligible product developer sufficient quantities of the covered product on commercially reasonable, market-based terms—
for a covered product that is subject to a REMS with ETASU, by 31 days after the later of—
Authorization for covered product subject to a REMS with ETASU
Request
An eligible product developer may submit to the Secretary a written request for the eligible product developer to be authorized to obtain sufficient quantities of an individual covered product subject to a REMS with ETASU.
Authorization
Not later than 120 days after the date on which a request under clause (i) is received, the Secretary shall, by written notice, authorize the eligible product developer to obtain sufficient quantities of an individual covered product subject to a REMS with ETASU for purposes of—
development and testing that involves human clinical trials, if the eligible product developer has—
Notice
A covered product authorization issued under this subparagraph shall state that the provision of the covered product by the license holder under the terms of the authorization will not be a violation of the REMS for the covered product.
Affirmative defense
In a civil action brought under paragraph (1), it shall be an affirmative defense, on which the defendant has the burden of persuasion by a preponderance of the evidence—
that, on the date on which the eligible product developer requested to purchase sufficient quantities of the covered product from the license holder—
that—
that the license holder made an offer to the individual specified pursuant to paragraph (2)(A)(iii)(III), by a means of communication (electronic, written, or both) specified pursuant to such paragraph, to sell sufficient quantities of the covered product to the eligible product developer at commercially reasonable market-based terms—
Remedies
In general
If an eligible product developer prevails in a civil action brought under paragraph (1), the court shall—
award to the eligible product developer a monetary amount sufficient to deter the license holder from failing to provide eligible product developers with sufficient quantities of a covered product on commercially reasonable, market-based terms, if the court finds, by a preponderance of the evidence—
Maximum monetary amount
A monetary amount awarded under subparagraph (A)(iii) shall not be greater than the revenue that the license holder earned on the covered product during the period—
beginning on—
for a covered product that is subject to a REMS with ETASU, the date that is 31 days after the later of—
Avoidance of delay
The court may issue an order under subparagraph (A)(i) before conducting further proceedings that may be necessary to determine whether the eligible product developer is entitled to an award under clause (ii) or (iii) of subparagraph (A), or the amount of any such award.
Limitation of liability
A license holder for a covered product shall not be liable for any claim under Federal, State, or local law arising out of the failure of an eligible product developer to follow adequate safeguards to assure safe use of the covered product during development or testing activities described in this section, including transportation, handling, use, or disposal of the covered product by the eligible product developer.
Omitted
Rule of construction
Definition
In this subsection, the term “antitrust laws”—
Antitrust laws
Nothing in this section shall be construed to limit the operation of any provision of the antitrust laws.
Omitted
Rule of construction
Nothing in this section, the amendments made by this section, or in section 355–1 of this title, shall be construed as—
(Pub. L. 116–94, div. N, title I, § 610, Dec. 20, 2019, 133 Stat. 3130.)